Intestinal Research

Volume 19(2); April 2021

Statement

Cancer

Clinical practice guideline for endoscopic resection of early gastrointestinal cancer: Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Si Hyung Lee, Jung Ho Bae, Hyunsoo Chung, Kee Don Choi, Jun Chul Park, Hyuk Lee, Min-Seob Kwak, Bun Kim, Hyun Jung Lee, Hye Seung Lee, Miyoung Choi, Dong-Ah Park, Jong Yeul Lee, Jeong-Sik Byeon, Chan Guk Park, Joo Young Cho, Soo Teik Lee, Hoon Jai Chun; Intest Res 2021;19(2):127-157. Published online October 13, 2020; DOI: https://doi.org/10.5217/ir.2020.00020

Abstract PDF Supplementary Material PubReader ePub

Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.

Citations

Citations to this article as recorded by

Distinct genomic, transcriptomic, and immune profiles for tumor and non-tumor mucosal regions in early gastric cancer
You Jeong Heo, Soomin Ahn, So Young Kang, Hyunjin Kim, Byung-Hoon Min, Kyoung-Mee Kim
Pathology - Research and Practice.2025; 266: 155768. CrossRef
Endoscopic submucosal dissection for superficial ultra-low rectal tumors: outcomes and predictive factors for procedure difficulty
Yinxin Wu
American Journal of Cancer Research.2024; 14(12): 5784. CrossRef
A proposal for grading the risk of lymph node metastasis after endoscopic resection of T1 colorectal cancer
Zhenghua Piao, Rong Ge, Chunnian Wang
International Journal of Colorectal Disease.2023;[Epub] CrossRef
A DSC Test for the Early Detection of Neoplastic Gastric Lesions in a Medium-Risk Gastric Cancer Area
Valli De Re, Stefano Realdon, Roberto Vettori, Alice Zaramella, Stefania Maiero, Ombretta Repetto, Vincenzo Canzonieri, Agostino Steffan, Renato Cannizzaro
International Journal of Molecular Sciences.2023; 24(4): 3290. CrossRef
Chasm between Public Perceptions and Epidemiological Data on Colorectal Cancer
Su Bee Park, Min Seob Kwak, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2023; 17(3): 449. CrossRef
Calcium, Vitamin D, and Colorectal Cancer
Young-Jo Wi, Soo-Young Na
The Korean Journal of Gastroenterology.2023; 82(2): 47. CrossRef
Effectiveness and Safety of Endoscopic Submucosal Dissection for Colorectal Neoplasm in Patients with High Charlson Comorbidity Index Score: A HASID Multicenter Study
Dong-Hyun Kim, Yong-Wook Jung, Byung-Chul Jin, Hyung-Hoon Oh, Hyo-Yeop Song, Seong-Jung Kim, Dae-Seong Myung, Sang-Wook Kim, Jun Lee, Geom-Seog Seo, Young-Eun Joo, Hyun-Soo Kim
Journal of Clinical Medicine.2023; 12(19): 6255. CrossRef
Endoscopic management of pseudo-lumen stapling following laparoscopic esophagojejunostomy: A case report
Seung Soo Lee
International Journal of Surgery Case Reports.2023; 111: 108830. CrossRef
Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim
Intestinal Research.2023; 21(4): 510. CrossRef
Summary and comparison of recently updated post-polypectomy surveillance guidelines
Yoon Suk Jung
Intestinal Research.2023; 21(4): 443. CrossRef
Advanced Endoscopic Resection Techniques in Cirrhosis—A Systematic Review and Meta-Analysis of Outcomes
Saurabh Chandan, Smit Deliwala, Shahab R. Khan, Daryl Ramai, Babu P. Mohan, Mohammad Bilal, Antonio Facciorusso, Lena L. Kassab, Faisal Kamal, Banreet Dhindsa, Abhilash Perisetti, Douglas G. Adler
Digestive Diseases and Sciences.2022; 67(10): 4813. CrossRef
Prognosis and risk factors of electrocoagulation syndrome after endoscopic submucosal dissection in the colon and rectum. Large cohort study
Seong-Jung Kim, Su Young Kim, Jun Lee
Surgical Endoscopy.2022; 36(8): 6243. CrossRef
Comparison between Endoscopic Submucosal Dissection and Surgery in Patients with Early Gastric Cancer
Meng Qian, Yuan Sheng, Min Wu, Song Wang, Kaiguang Zhang
Cancers.2022; 14(15): 3603. CrossRef
Endoscopic methods for the detection and treatment of gastric cancer
Negar Niknam, Steven Obanor, Linda A. Lee
Current Opinion in Gastroenterology.2022; 38(5): 436. CrossRef
Association Between Family History of Gastric Cancer and the Risk of Gastric Cancer and Adenoma: A Nationwide Population-Based Study
Yoon Suk Jung, Mai Thi Xuan Tran, Boyoung Park, Chang Mo Moon
American Journal of Gastroenterology.2022; 117(8): 1255. CrossRef
Colonic Chicken Skin Mucosa Surrounding Colon Polyps Is an Endoscopic Predictive Marker for Colonic Neoplastic Polyps
Yu Mi Lee, Kyung Ho Song, Hoon Sup Koo, Choong-Sik Lee, Inseok Ko, Sang Hyuk Lee, Kyu Chan Huh
Gut and Liver.2022; 16(5): 754. CrossRef
Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef
Feasibility of same-day discharge following endoscopic submucosal dissection for esophageal or gastric early cancer
Jing Wang, Shi-Jie Li, Yan Yan, Peng Yuan, Wei-Feng Li, Chang-Qi Cao, Wei-Gang Chen, Ke-Neng Chen, Qi Wu
World Journal of Gastroenterology.2022; 28(41): 5957. CrossRef
Endoscopic, clinicopathological, and growth characteristics of minute gastric cancer
Zhu Hui Liu, Shi Yuan Lu, Xiao Bo Li, Hui Min Chen, Hao Yan Chen, Xiao Yu Chen, Jing‐Yuan Fang, Yun Cui
Journal of Digestive Diseases.2022; 23(11): 628. CrossRef
Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer
Darina Kohoutova, Matthew Banks, Jan Bures
Cancers.2021; 13(24): 6242. CrossRef

9,607 View
278 Download
24 Web of Science
20 Crossref

Reviews

IBD

The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease: Steven Nicolaides, Abhinav Vasudevan, Tony Long, Daniel van Langenberg; Intest Res 2021;19(2):158-170. Published online October 13, 2020; DOI: https://doi.org/10.5217/ir.2020.00008

Abstract PDF PubReader ePub

Smoking significantly increases the risk of developing and worsens Crohn’s disease (CD), yet protects against the development and reduces the severity of ulcerative colitis. It is less clear whether smoking impacts the efficacy of therapeutics in inflammatory bowel disease (IBD). We review the literature regarding the relationship between smoking and the efficacy of medical and surgical therapy in IBD. Smoking is associated with alterations in thiopurine metabolism and may affect time to disease relapse. The outcomes of anti-tumor necrosis factor therapy in active smokers appear neutral with data lacking for newer biologics. Smoking increases the risk of postoperative recurrence in those requiring resection for CD, likely attributable to perturbations of the gut microbiota although further implications of these for disease onset/progression and treatment efficacy remain unclear. Multiple lifestyle and psychosocial confounders are likely under-recognized cofactors in the association between smoking and IBD. Despite the widely promulgated risks associated with cigarette smoking in CD, more incisive data are required to further elucidate the actual relationship between smoking and disease pathways, while accounting for the several negative cofactors prevalent in smokers which cast uncertainty on the magnitude of the direct effect of smoking on disease pathophysiology and the efficacy of therapy.

Citations

Citations to this article as recorded by

DAMP-ing IBD: Extinguish the Fire and Prevent Smoldering
Oliver Sandys, Pieter C. F. Stokkers, Anje A. te Velde
Digestive Diseases and Sciences.2025; 70(1): 49. CrossRef
The Effects of Combustible Cigarettes and Electronic Nicotine Delivery Systems on Immune Cell-Driven Inflammation and Mucosal Healing in Ulcerative Colitis
Nikolina Kastratovic, Vladimir Markovic, Aleksandar Arsenijevic, Ana Volarevic, Natasa Zdravkovic, Marija Zdravkovic, Marija Brankovic, Tijana Gmizic, Carl Randall Harrell, Vladimir Jakovljevic, Valentin Djonov, Vladislav Volarevic
Nicotine and Tobacco Research.2025; 27(3): 542. CrossRef
Smoking Experience before Adulthood Is Associated with an Increased Risk of Developing Ulcerative Colitis in Adult Ex-Smokers
Yu Kyung Jun, Bongseong Kim, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Kyungdo Han, Hyuk Yoon
Yonsei Medical Journal.2025; 66(1): 9. CrossRef
Recurrence rates after strictureplasty for small bowel Crohn's disease remain high in the era of biologics
A. Nasasra, T. E. M. Morrison, A. Luberto, M. Carvello, K. J. Williams, J. Davies, A. Spinelli, A. M. Mehta, J. H. Warusavitarne
Colorectal Disease.2025;[Epub] CrossRef
The Importance of Nutriepigenetics in Older Adults with Inflammatory Bowel Disease
Ana-Gabriela Prada, Costina Daniela Gîță, Sandra Monica Gîdei, Doina Istratescu, Tudor Stroie, Sorina Maria Aurelian, Gabriel Ioan Prada, Ovidiu Nicolae Penes, Anca Lucia Pop, Mihai Mircea Diculescu
Nutrients.2025; 17(4): 620. CrossRef
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus
Shubha Bhat, Ruishen Lyu, Mitali Agarwal, Michelle Becker, Richard Bloomfeld, David H Bruining, Benjamin L Cohen, Marina Ivanov, Jonathan A Leighton, Alyssa P Stewart, Lindsay Trocke, Stacy S Tse, Ryan C Ungaro, Byron P Vaughn, Miguel Regueiro, Erick Sokn
Inflammatory Bowel Diseases.2024; 30(6): 950. CrossRef
Duration of smoking cessation in patients with inflammatory bowel disease
Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Federico Bertoletti, Antonio Giordano, Alberto López-Faba, Esther García-Planella
Gastroenterología y Hepatología.2024; 47(6): 591. CrossRef
Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study
Cemile Cansu Alperen, Barıs Soydas, Ender Serin, Mustafa Erbayrak, Nurten Akyurek Savas, Gulhan Kanat Unler, Cenk Emre Meral, Ugur Toprak, Ahmet Sedat Boyacioglu, Ulku Dagli
Digestive Diseases and Sciences.2024; 69(8): 2927. CrossRef
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Rocío Ferreiro‐Iglesias, Sol Porto Silva, Sandra Marín, María José Casanova, Míriam Mañosa, Carlos González‐Muñoza, Ruth de Francisco, Berta Caballol, Lara Arias, Marta Piqueras, Yamile Zabana, Montserrat Rivero, Xavier Calvet, Francisco Mesonero, Pilar V
Alimentary Pharmacology & Therapeutics.2024; 60(5): 604. CrossRef
Akkermansia muciniphila and Parabacteroides distasonis as prognostic markers for relapse in ulcerative colitis patients
Ana Mendes-Frias, Marta Moreira, Maria C. Vieira, Joana Gaifem, Patrício Costa, Luís Lopes, Ricardo Silvestre
Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef
Duration of smoking cessation in patients with inflammatory bowel disease
Carlos González-Muñoza, Cristina Gely, Jordi Gordillo, Federico Bertoletti, Antonio Giordano, Alberto López-Faba, Esther García-Planella
Gastroenterología y Hepatología (English Edition).2024; 47(6): 591. CrossRef
Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease—A Prospective Multicenter Cohort Study
Mirabella Zhao, Lone Larsen, Anders Dige, Anja Poulsen, Bobby Lo, Mohamed Attauabi, Pernille Dige Ovesen, Mads Damsgaard Wewer, Dagmar Christiansen, Christian Lodberg Hvas, Andreas Munk Petersen, Flemming Bendtsen, Jakob Seidelin, Johan Burisch
Journal of Crohn's and Colitis.2024;[Epub] CrossRef
Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019
Ryan A. Jasper, Po‐Hung Chen, Reeha Patel, Shelly Joseph, Steven D. Miller, Susan Hutfless
JGH Open.2023; 7(4): 291. CrossRef
Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
Jiryeon Jang, Sehoon Jeong
BioChip Journal.2023; 17(4): 403. CrossRef
High-Dimensional DNA Methylation Mediates the Effect of Smoking on Crohn’s Disease
Tingting Wang, Pingtian Xia, Ping Su
Frontiers in Genetics.2022;[Epub] CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Clinical profile, course and outcomes of adults with inflammatory bowel disease over a decade: a single center experience
Reham Saleh Aljohani, Ali Alaklabi, Yumna Mohammed Alsitary, Majd Abdulrahman bin Khunayn, Shahd Omar Hijazi, Rema Ibraheem Alshagary, Rajkumar Rajendram
Annals of Saudi Medicine.2022; 42(6): 397. CrossRef

9,306 View
202 Download
18 Web of Science
17 Crossref

IBD

Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know?: Nor Hamizah Shafiee, Zahara Abdul Manaf, Norfilza M. Mokhtar, Raja Affendi Raja Ali; Intest Res 2021;19(2):171-185. Published online February 3, 2021; DOI: https://doi.org/10.5217/ir.2020.00035

Abstract PDF PubReader ePub

Current treatment for inflammatory bowel disease (IBD) includes the application of anti-inflammatory agents for the induction and remission of IBD. However, prolonged use of anti-inflammatory agents can exert adverse effects on patients. Recently, formulated dietary approach in treating IBD patients is utilized to improve clinical activity scores. An alteration of gastrointestinal microbiota through dietary therapy was found to reduce IBD and is recognized as a promising therapeutic strategy for IBD. One of the recommended formulated diets is an anti-inflammatory diet (AID) that restricts the intake of carbohydrates with modified fatty acids. This diet also contains probiotics and prebiotics that can promote balanced intestinal microbiota composition. However, scientific evidences are limited to support this specific dietary regime in maintaining the remission and prevention relapse of IBD. Therefore, this review aimed to summarize available data from various studies to evaluate the AID diet effectiveness which will be useful for clinicians to manage their IBD patients by application of improved dietary therapy.

Citations

Citations to this article as recorded by

Role of Nutrition in the Management of Inflammatory Bowel Disease
Khalid Nawaz, Iqr a, Muneeb Ullah, Jin-Wook Yoo, Umme Aiman, Madiha Ghazanfar, Muhammad Naeem
Recent Progress in Nutrition.2025; 05(01): 1. CrossRef
Diet and Nutrition in Inflammatory Bowel Disease: A Review of the Literature
Scott Manski, Nicholas Noverati, Tatiana Policarpo, Emily Rubin, Raina Shivashankar
Crohn's & Colitis 360.2024;[Epub] CrossRef
Adverse Food Reactions in Inflammatory Bowel Disease: State of the Art and Future Perspectives
Ivan Capobianco, Federica Di Vincenzo, Pierluigi Puca, Guia Becherucci, Maria Chiara Mentella, Valentina Petito, Franco Scaldaferri
Nutrients.2024; 16(3): 351. CrossRef
Nutritional Profile, Disease Severity, and Quality of Life of Patients with Inflammatory Bowel Disease: A Case–Control Study
Lea N. Sayegh, Firas Haddad, Layane Bou Jaoude, Nicole Fakhoury-Sayegh, Gessica N. H. A. Heraoui, Zainab Nasrallah, Charbel Chidiac, Rashad Nawfal, Fadi F. Francis, Fadi H. Mourad, Jana G. Hashash
Nutrients.2024; 16(12): 1826. CrossRef
Dietary Profile of Patients with Inflammatory Bowel Disease in Clinical Remission—A Preliminary Study
Raquel Susana Torrinhas, Ilanna Marques Gomes da Rocha, Danielle Cristina Fonseca, Helena Menezes, Ana Paula Prudêncio, Bianca Depieri Balmant, Letícia Callado, Adérson Omar Mourão Cintra Damião, Natalia Queiroz, Dan L. Waitzberg
Nutrients.2024; 16(14): 2227. CrossRef
Mixed-method Irish study exploring the role of diet in IBD based on an online questionnaire and a patient panel opinion
Naomi Hanrahan, Victoria Spillane, Kevin Moore, Mick Dineen, Aoife Murphy, Ana Velikonja, Margot Hurley, Majella O’Keeffe, Silvia Melgar
BMJ Open Gastroenterology.2024; 11(1): e001251. CrossRef
Medicinal Herbs for the Treatment of Peptic Ulcers
Divyansh Tiwari, Aftab Alam, Shivang Dhoundiyal, Shaweta Sharma, Shikha Yadav
Current Traditional Medicine.2024;[Epub] CrossRef
Comparison and recommendation of dietary patterns based on nutrients for Eastern and Western patients with inflammatory bowel disease
Yue Hou, Sai-Feng Wang, Ke Zhou, Shi-Xue Dai
Frontiers in Nutrition.2023;[Epub] CrossRef
Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study
Oh Chan Kwon, Yuna Kim, Jaeyoung Chun, Kyungdo Han, Min-Chan Park, Ryul Kim, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
Frontiers in Medicine.2023;[Epub] CrossRef
The importance of anti-inflammatory diet in depression: a literature review and recommendations
Zuzanna Joanna Wingralek, Paweł Miś, Hubert Wróblewski, Aleksandra Zimna, Joanna Rog
Current Problems of Psychiatry.2023; 24: 134. CrossRef
Mobile-based program improves healthy eating of ulcerative colitis patients: A pilot study
Wenjing Tu, Shuxia Yan, Tingting Yin, Sumin Zhang, Wenjing Xu, Ping Zhang, Guihua Xu
DIGITAL HEALTH.2023;[Epub] CrossRef
A Specific Carbohydrate Diet Virtual Teaching Kitchen Curriculum Promotes Knowledge and Confidence in Caregivers of Pediatric Patients with Inflammatory Bowel Disease
Nancy Rivera, Kaylie Nguyen, Venus Kalami, Feifei Qin, Maya B. Mathur, Rebecca Blankenburg, Ann Ming Yeh
Nutrients.2023; 15(18): 3999. CrossRef
Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review
Matthew D Coates, Kofi Clarke, Emmanuelle Williams, Nimalan Jeganathan, Sanjay Yadav, David Giampetro, Vitaly Gordin, Sadie Smith, Kent Vrana, Anne Bobb, Thu Thi Gazzio, Heather Tressler, Shannon Dalessio
Crohn's & Colitis 360.2023;[Epub] CrossRef
Lupeol Esters from the Edible Tubers of American Groundnut (Apios americana)
Alec P. Brundle, Nanea K. Perkins, Mackenzie J. Perpetua, Natalie C. Stagnitti, Emily J. Schafer, Kristopher J. Kolonko, Stephen T. Deyrup
ACS Food Science & Technology.2023; 3(12): 2250. CrossRef
Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed
Tiziana LARUSSA, Ludovico ABENAVOLI, Giulia FABIANO, Maria A. MANCUSO, Natale POLIMENI, Dan L. DUMITRASCU, Francesco LUZZA
Minerva Gastroenterology.2022;[Epub] CrossRef
Screening and Evaluation of Probiotics for Reducing Intestinal Inflammation
雅君陈
Hans Journal of Food and Nutrition Science.2022; 11(01): 44. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Egg white hydrolysate from simulated gastrointestinal digestion alleviates the inflammation and improves the nutritional status in TNBS-induced Crohn’s disease rats
Tianliang Wu, Juanrui Li, Wei Wang, Chenxi Xu, Liying Wang, Long Ding
Journal of Functional Foods.2022; 98: 105288. CrossRef
Development and Validation of a Smartphone Application for Telenutrition in Patients with Inflammatory Bowel Disease
Arti Gupta, Namrata Singh, Divya Madan, Mariyam Farooqui, Neha Singh, David Mathew Thomas, Bhaskar Kante, Mukesh Singh, Shubi Virmani, Mehak Verma, Aditya Bajaj, Manasvini Markandey, Peeyush Kumar, Sudheer Kumar Vuyyuru, Pabitra Sahu, Nitika Monga, Govind
Diagnostics.2022; 12(10): 2482. CrossRef
Budesonide and the Gluten Containing Elimination Diet as Treatments for Non‐responsive Celiac Disease in Children
Awab Ali Ibrahim, Victoria Kenyon, Alessio Fasano, Maureen M. Leonard
Journal of Pediatric Gastroenterology and Nutrition.2022; 75(5): 616. CrossRef
Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis
Aditi Saha, Isabella Dreyfuss, Humaira Sarfraz, Mark Friedman, Joseph Markowitz
Cancers.2022; 15(1): 84. CrossRef
Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions?
Lorenzo Bertani, Davide Giuseppe Ribaldone, Massimo Bellini, Maria Gloria Mumolo, Francesco Costa
Nutrients.2021; 13(4): 1387. CrossRef
Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
Intestinal Research.2021; 19(4): 478. CrossRef

10,281 View
308 Download
23 Web of Science
23 Crossref

Original Articles

Inflammatory Bowel Diseases

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018: Satimai Aniwan, Julajak Limsrivilai, Supot Pongprasobchai, Nonthalee Pausawasdi, Piyapan Prueksapanich, Natanong Kongtub, Rungsun Rerknimitr; Intest Res 2021;19(2):186-193. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00028

Abstract PDF PubReader ePub

Background/Aims
The incidence of ulcerative colitis (UC) in Thailand (crude incidence rate of 0.28 per 100,000 persons) is much lower than in the West. The burden of UC varies in different populations. The aim of this study was to evaluate the natural history of UC over the two decades in Bangkok, Thailand.
Methods
This retrospective study included patients who were diagnosed with UC between 2000 and 2018 in 2 university hospitals. To evaluate changes in the disease course, we stratified patients into 2000–2009 cohort and 2010–2018 cohort. The cumulative probability of endoscopic healing, UC-related hospitalization and colectomy was estimated using the Kaplan-Meier method.
Results
A total of 291 UC patients were followed for total of 2,228 person-years. Comparison between 2 cohorts, there were no differences in disease pattern and severity whereas an increase in the combination use of oral and topical mesalamine and the early use of thiopurine was observed. Only 1% of patients for each cohort required biologic agent at 5 years. The rate of achieving mucosal healing increased from 15% to 46% at 3 years (P< 0.01). The rate of UC-related hospitalization decreased from 30% to 21% at 5 years (P< 0.05). The rate of colectomy decreased from 6% to 2% at 5 years (P< 0.05).
Conclusions
The natural history of UC in a low incidence country was less aggressive than the West. Over the past two decades, the rates of UC-related hospitalization and colectomy have been decreasing which were similar to the West.

Citations

Citations to this article as recorded by

Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis
Ahmed Mohsin Huran Al-Jawadri, Zahra Karami, Ismaeil Haririan, Mohammad Akrami, Mahdi Gholami
Journal of Drug Targeting.2025; : 1. CrossRef
Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Digestive Diseases and Sciences.2023; 68(6): 2165. CrossRef
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis
Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel
Digestive Diseases and Sciences.2022; 67(7): 2866. CrossRef
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
Gut and Liver.2022; 16(1): 138. CrossRef
Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
Journal of Personalized Medicine.2022; 12(3): 507. CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
United European Gastroenterology Journal.2022; 10(10): 1063. CrossRef
Current status of IBD and surgery of Crohn's disease in Thailand
Woramin Riansuwan, Julajak Limsrivilai
Annals of Gastroenterological Surgery.2021; 5(5): 597. CrossRef
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
Gut and Liver.2021; 15(6): 942. CrossRef

6,797 View
187 Download
13 Web of Science
13 Crossref

Inflammatory Bowel Diseases

Yarrow oil ameliorates ulcerative colitis in mice model via regulating the NF-κB and PPAR-γ pathways: Maged E. Mohamed, Sahar A. Elsayed, Hafez R. Madkor, Heba M. Saad Eldien, Omar M. Mohafez; Intest Res 2021;19(2):194-205. Published online August 21, 2020; DOI: https://doi.org/10.5217/ir.2020.00021

Abstract PDF PubReader ePub

Background/Aims
Ulcerative colitis (UC) is a chronic inflammatory disorder with indefinite etiology; however, environmental, genetic, immune factors and microbial agents could be implicated in its pathogenesis. UC treatment is lifelong, therefore; the potential side effects and cost of the therapy are significant. Yarrow is a promising medicinal plant with the ability to treat many disorders, owing to its bioactive compounds especially the essential oil. The main aim of this research was to investigate the therapeutic effect of the yarrow oil on colitis including the involved mechanism of action.
Methods
In 21-female C57BL/6 mice were divided into 3 groups; control group, colitis model group, and oil-treated group. Groups 2 and 3 received 5% dextran sulfate sodium (DSS) in drinking water for 9 days, and concomitantly, only group 3 was given 100 mg/kg yarrow oil. Mice were examined for their body weight, stool consistency and bleeding, and the disease activity indexes were calculated.
Results
Oral administration of yarrow oil markedly repressed the severity of UC via the reduction of the inflammatory signs and restoring colon length. The oil was able to down-regulate nuclear factor kappa light chain enhancer of activated B cells (NF-κB), up-regulate peroxisome proliferator-activated receptor gamma (PPAR-γ), and enhance transforming growth factor-β expression. The oil normalized the tumor necrosis factor-α expression, restored the normal serum level of interleukin-10 (IL-10) and reduced the serum level of IL-6.
Conclusions
Yarrow oil mitigated UC symptoms and regulated the inflammatory cytokines secretion via regulation of NF-κB and PPAR-γ pathways in the mice model, however, this recommendation requires further investigations using clinical studies to confirm the use of the oil on humans.

Citations

Citations to this article as recorded by

Pyrazole derivatives ameliorate synovial inflammation in collagen-induced arthritis mice model via targeting p38 MAPK and COX-2
Ahlam M. Abdallah, Amany H. Abdel Naiem, Salama R. Abdelraheim, Omar M. Mohafez, Hend M. Abdelghany, Sahar A. Elsayed, Wafaey Gomaa, Heba Marey
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(1): 819. CrossRef
Investigation of Yarrow Essential Oil Composition and Microencapsulation by Complex Coacervation Technology
István Székely-Szentmiklósi, Emőke Margit Rédai, Béla Kovács, Attila-Levente Gergely, Csilla Albert, Zoltán-István Szabó, Blanka Székely-Szentmiklósi, Emese Sipos
Applied Sciences.2024; 14(17): 7867. CrossRef
Therapeutic Potential of Essential Oils Against Ulcerative Colitis: A Review
Jinkai Li, Xiaofei Zhang, Fei Luan, Jiawei Duan, Junbo Zou, Jing Sun, Yajun Shi, Dongyan Guo, Changli Wang, Xiao Wang
Journal of Inflammation Research.2024; Volume 17: 3527. CrossRef
Bioactive Natural Leads and Traditional Herbal Plants in the Management of Inflammatory Bowel Diseases: A Brief Review
Sonia Chauhan, Sakshi Sharma, Rupa Mazumder, Nidhi Sharma
Letters in Drug Design & Discovery.2024; 21(12): 2288. CrossRef
Costunolide and dehydrocostus lactone alleviate ulcerative colitis via regulating TLR4, NF-κB and PI3K expression
Songting Liang, Chu Chen, Ruoshi Li, Guihua Jiang, Leilei Du
Scientific Reports.2024;[Epub] CrossRef
Plant Essential Oils as Healthy Functional Ingredients of Nutraceuticals and Diet Supplements: A Review
Riccardo Matera, Elena Lucchi, Luca Valgimigli
Molecules.2023; 28(2): 901. CrossRef
Exploring the Medicinal Potential of Achillea grandifolia in Greek Wild-Growing Populations: Characterization of Volatile Compounds, Anti-Inflammatory and Antioxidant Activities of Leaves and Inflorescences
Olga S. Tsiftsoglou, Maria-Eleni Atskakani, Nikos Krigas, Michalis K. Stefanakis, Christos Gounaris, Dimitra Hadjipavlou-Litina, Diamanto Lazari
Plants.2023; 12(3): 613. CrossRef
The Potential of Natural Oils to Improve Inflammatory Bowel Disease
Yaxi Zhou, Diandian Wang, Hao Duan, Shiqi Zhou, Jinhong Guo, Wenjie Yan
Nutrients.2023; 15(11): 2606. CrossRef
Variability in the volatile constituents and biological activities of Achillea millefolium L. essential oils obtained from different plant parts and by different solvents
Hamdoon A. Mohammed, Muhamad Abd-Elraouf, Ghassan M Sulaiman, Suliman A. Almahmoud, Fatma A. Hamada, Riaz A. Khan, Mostafa M. Hegazy, Mohammed F. Abd-El-Wahab, Taha A Kedra, Ahmed Ismail
Arabian Journal of Chemistry.2023; 16(9): 105103. CrossRef
Mesosphaerum suaveolens Essential Oil Attenuates Inflammatory Response and Oxidative Stress in LPS-Stimulated RAW 264.7 Macrophages by Regulating NF-κB Signaling Pathway
Omprakash Mohanta, Asit Ray, Sudipta Jena, Ambika Sahoo, Soumya Swarup Panda, Prabhat Kumar Das, Sanghamitra Nayak, Pratap Chandra Panda
Molecules.2023; 28(15): 5817. CrossRef
Effect of Piper nigrum essential oil in dextran sulfate sodium (DSS)-induced colitis and its potential mechanisms
Yeye Hu, Ziliang He, Ji Zhang, Chaohua Zhang, Yanting Wang, Wei Zhang, Fenglun Zhang, Weiming Zhang, Fenglin Gu, Weicheng Hu
Phytomedicine.2023; 119: 155024. CrossRef
Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef
Chitosan Oligosaccharides Alleviate Colitis by Regulating Intestinal Microbiota and PPARγ/SIRT1-Mediated NF-κB Pathway
Congcong Guo, Yue Zhang, Tao Ling, Chongjie Zhao, Yanru Li, Meng Geng, Sailun Gai, Wei Qi, Xuegang Luo, Liehuan Chen, Tongcun Zhang, Nan Wang
Marine Drugs.2022; 20(2): 96. CrossRef
TMT labeled comparative proteomic analysis reveals spleen active immune responses during Clostridium perfringens type C infected piglet diarrhea
Xiaoli Wang, Xiaoyu Huang, Qiaoli Yang, Zunqiang Yan, Pengfei Wang, Xiaoli Gao, Ruirui Luo, Shuangbao Gun
PeerJ.2022; 10: e13006. CrossRef
Exploring compounds to be used as cosmetic agents that activate peroxisome proliferator‐activated receptor alpha
Keisuke Tachibana, Syohei Fukuda, Jun Fukushima, Kenji Ishimoto, Masahiro Sakata, Yasutomo Nishimori, Takefumi Doi
International Journal of Cosmetic Science.2022; 44(2): 189. CrossRef
Prevention of Ulcerative Colitis in Mice by Sweet Tea (Lithocarpus litseifolius) via the Regulation of Gut Microbiota and Butyric-Acid-Mediated Anti-Inflammatory Signaling
Xiao-Qin He, Dan Liu, Hong-Yan Liu, Ding-Tao Wu, Hua-Bin Li, Xin-Shang Zhang, Ren-You Gan
Nutrients.2022; 14(11): 2208. CrossRef
In Vivo Immune Study of Achillea Fragrantissima Extract Versus Echinaid and Endoxan in Wistar Rats
Raghad Mohammad Alhomaid, Yousef Mesfer Alharbi, Reham Mohammad Algheshairy, Mona Sulaiman Almujaydil, Hend Faisal Alharbi, Hoda Ali Ali
Current Research in Nutrition and Food Science Journal.2022; 10(2): 733. CrossRef
Achillea millefolium Essential Oil Mitigates Peptic Ulcer in Rats through Nrf2/HO-1 Pathway
Manar K. Alomair, Lama S. Alabduladheem, Marwah A. Almajed, Amjad A. Alobaid, Essraa A. R. Alkhalifah, Nancy S. Younis, Maged E. Mohamed
Molecules.2022; 27(22): 7908. CrossRef
Validation of the Anti-Inflammatory Effect of Tenebrio Molitor Larva Oil in a Colitis Mouse Model
B. M. Park, J. Lee, Bock Gie Jung, Bong Joo Lee
Folia Biologica.2022; 68(2): 50. CrossRef
Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats
Bolin Li, Pengli Du, Yao Du, Danyang Zhao, Yanru Cai, Qian Yang, Zijing Guo
Life Sciences.2021; 269: 119008. CrossRef

8,926 View
196 Download
21 Web of Science
20 Crossref

Inflammatory Bowel Diseases

Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry: Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao; Intest Res 2021;19(2):206-216. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09169

Abstract PDF PubReader ePub

Background/Aims
The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India.
Methods
A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed.
Results
A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south.
Conclusions
The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.

Citations

Citations to this article as recorded by

Diverse Phenotypes, Consistent Treatment: A Study of 30 997 South Asian and White Inflammatory Bowel Disease Patients Using the UK Inflammatory Bowel Disease BioResource
Sharmili Balarajah, Laura Martinez-Gili, James Leslie Alexander, Benjamin Harvey Mullish, Robert William Perry, Jia V Li, Julian Roberto Marchesi, Miles Parkes, Timothy Robin Orchard, Lucy Charlotte Hicks, Horace Richard Timothy Williams
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Inflammatory bowel disease in south Asia: a scoping review
Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
The Lancet Gastroenterology & Hepatology.2025; 10(3): 259. CrossRef
Comparison of 1‐Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study
Luan Minh Dang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Hoang Huu Bui, Chuong Dinh Nguyen, Chi Thi Nguyen, Nam Hoai Nguyen, Hien Thi‐Thu Nguyen, Nga Thi Dinh, Lien Thi‐Phuong Nguyen, Khien Van Vu, Minh Cuong Duong
JGH Open.2025;[Epub] CrossRef
Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019
Suprabhat Giri, Anuraag Jena, Praveen Kumar-M, Jaikumar Rajavoor Muniswamy, Preetam Nath, Vishal Sharma
Intestinal Research.2025;[Epub] CrossRef
Dietary essential oil components: A systematic review of preclinical studies on the management of gastrointestinal diseases
Rajiv Gandhi Gopalsamy, Poovathumkal James Antony, Kumaraswamy Athesh, Varghese Edwin Hillary, Monalisa Martins Montalvão, Govindasamy Hariharan, Lucas Alves da Mota Santana, Lysandro Pinto Borges, Ricardo Queiroz Gurgel
Phytomedicine.2025; 140: 156630. CrossRef
FoxP3-positive T regulatory cells and its effector mechanisms in Crohn’s disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies
Susama Patra, Shalini Chaudhary, Subash Chandra Samal, Pavithra Ayyanar, Somanath Padhi, Hemanta Kumar Nayak, Amit Kumar Satapathy, Saurav Nayak, Ajit Sahu, Tapaskanti Parida, Mohammed Shahin
European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis
Caroline Tianeze de Castro, Douglas da Silva Oliveira, Fabrício Freire de Melo, Mauricio Lima Barreto, Carlos Antonio de Souza Teles Santos, Djanilson Barbosa dos Santos
Scandinavian Journal of Gastroenterology.2025; : 1. CrossRef
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
Arshdeep Singh, Manjeet Kumar Goyal, Vandana Midha, Ramit Mahajan, Kirandeep Kaur, Yogesh Kumar Gupta, Dharmatma Singh, Namita Bansal, Ramandeep Kaur, Shivam Kalra, Omesh Goyal, Varun Mehta, Ajit Sood
American Journal of Gastroenterology.2024; 119(7): 1365. CrossRef
Clinical profile of patients with ulcerative colitis- A hospital based study from Madhya Pradesh
Mayank Jain
Indian Journal of Gastroenterology.2024; 43(1): 274. CrossRef
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intestinal Research.2023; 21(1): 137. CrossRef
Gender Differences in Psychological Symptoms and Quality of Life in Patients with Inflammatory Bowel Disease in China: A Multicenter Study
Chuan Liu, Jixiang Zhang, Min Chen, Ping An, Jiankang Xiang, Rong Yu, Suqi Zeng, Shuchun Wei, Beiying Deng, Zhongchun Liu, Changqing Jiang, Jie Shi, Kaichun Wu, Weiguo Dong
Journal of Clinical Medicine.2023; 12(5): 1791. CrossRef
Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn’s disease: A cohort study from northern India
Arshdeep Singh, Chandan Kakkar, Shreya Garg, Kirti Arora, Vandana Midha, Ramit Mahajan, Satpal Singh Virk, Narender Pal Jain, Dharmatma Singh, Kriti Sood, Ashish Tripathi, Dhruv Gupta, Ishita Gupta Kaushal, Ritu Dhawan Galhotra, Kavita Saggar, Ajit Sood
Indian Journal of Gastroenterology.2023; 42(5): 668. CrossRef
Is disease activity associated with social support and psychological distress in Crohn’s disease patients? Results of a cross-sectional study in a Chinese hospital population
Mengting Huang, Lei Tu, Linxia Wu, Yan Zou, Xin Li, Xiaofei Yue, Chen Huang, Ping Lei, Qian Li, Ping Han, Lian Yang, Liangru Zhu
BMJ Open.2023; 13(10): e076219. CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Clostridioides Infection in Patients with Inflammatory Bowel Disease
Mi Rae Lee, Eun Soo Kim
The Korean Journal of Gastroenterology.2022; 80(2): 66. CrossRef
Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Byung Chul Jin, Hee Jin Moon, Sang Wook Kim
The Korean Journal of Gastroenterology.2022; 80(2): 72. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
Madhura Balasubramaniam, Neilanjan Nandi, Tina Aswani-Omprakash, Shaji Sebastian, Vishal Sharma, Parakkal Deepak, Shrinivas Bishu, Neha D. Shah, Sumit Bhatia, Tauseef Ali, Sharan Khela, Kiran Peddi
Gastroenterology.2022; 163(5): 1145. CrossRef
Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia
Madhura Balasubramaniam, Neilanjan Nandi, Tina Aswani-Omprakash, Shaji Sebastian, Vishal Sharma, Parakkal Deepak, Shrinivas Bishu, Neha D. Shah, Sumit Bhatia, Tauseef Ali, Sharan Khela, Kiran Peddi
Clinical Gastroenterology and Hepatology.2022; 20(11): 2421. CrossRef
Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
Gut and Liver.2022; 16(6): 907. CrossRef
Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study
You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim
Gut and Liver.2022; 16(6): 995. CrossRef
The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
United European Gastroenterology Journal.2022; 10(10): 1063. CrossRef
Sociodemographic Characteristics, Smoking, and Family History of Patients with Inflammatory Bowel Disease, Northern Part of Iraq
Blnd Ibrahim Mohammed, Bushra Karem Amin
Medical Journal of Babylon.2022; 19(4): 615. CrossRef
Inflammatory bowel diseases in Tamil Nadu: A survey of demographics, clinical profile, and practices
Rohan V Yewale, Kartik Natarajan, Jeyaraj Ubal Dhus, Sarojini Ashok Parameswaran, Kallipatti Ramaswamy Palaniswamy, Doraisamy Babu Vinish, Aravindh Somasundaram, Arulraj Ramakrishnan, Sibithooran Karmegam, Ramaswamy Saraswathy Arun, Ujjani Shankaraiah Man
JGH Open.2021; 5(11): 1306. CrossRef
Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?
Soo-Young Na, Yun-Jeong Lim
Diagnostics.2021; 11(12): 2240. CrossRef

14,508 View
503 Download
26 Web of Science
28 Crossref

Inflammatory Bowel Diseases

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience: Alexandra Cohen, Najma Ahmed, Ana Sant’Anna; Intest Res 2021;19(2):217-224. Published online April 22, 2020; DOI: https://doi.org/10.5217/ir.2019.09164

Abstract PDF PubReader ePub

Background/Aims
Despite the well-established efficacy of tumor necrosis factor (TNF) antagonists as treatment options for Crohn’s disease, many pediatric patients need a change in therapy due to adverse events and loss of response, highlighting the necessity for medications with a different mechanism of action. Ustekinumab has been shown to be effective in inducing clinical remission in some adults with disease refractory to anti-TNF agents, however, minimal data exists in the pediatric population.
Methods
We conducted a retrospective chart review of 11 pediatric patients receiving ustekinumab, specifically extracting baseline data, information on prior treatment and response, indications for starting ustekinumab, clinical information, and laboratory parameters pre- and post-therapy. Clinical response was defined as a decrease in abbreviated Pediatric Crohn’s Disease Activity Index score.
Results
Patients ranged from 12 to 17 years of age upon initiation of treatment with ustekinumab. Five of 11 patients demonstrated a clinical response. Among these patients, 2 remained in clinical remission, while the remaining 3 experienced a secondary loss of response. The other 6 patients were primary nonresponders who either remained unwell or demonstrated slight clinical worsening. All patients who clinically responded to ustekinumab and had an initially elevated CRP experienced complete normalization of their values. Mucosal healing was seen on endoscopy in 1 responder, with 2 other patients showing endoscopic improvement.
Conclusions
These results demonstrate for the first time that ustekinumab has the potential to induce not only clinical and biochemical remission, but also endoscopic improvement, in the pediatric population. Future research is needed to determine factors that influence response to therapy.

Citations

Citations to this article as recorded by

Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
Abdulhamid Alhadab, Amal Almarhoon, Amena AlAlwan, AbdelHai Hammo
Saudi Journal of Gastroenterology.2025; 31(2): 59. CrossRef
Oral manifestations of Crohn disease managed with ustekinumab
Patrick Ruck, Elizabeth S. Gosnell, James R. Rick
The Journal of the American Dental Association.2025; 156(2): 160. CrossRef
STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN
Gemma Pujol-Muncunill, Víctor Manuel Navas-López, Oren Ledder, Shlomi Cohen, Marina Lekar, Dan Turner, Kaija-Leena Kolho, Arie Levine, Nicholas M. Croft, Jiri Bronsky, Dror S. Shouval, Amit Assa, Rachel Harris, Fevronia Kiparissi, Marina Aloi, Nadeem Ahma
European Journal of Pediatrics.2024; 183(8): 3253. CrossRef
Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intestinal Research.2023; 21(1): 137. CrossRef
Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review
Shengbo Fang, Sixi Zhang, Chunyan Zhang, Libo Wang
Pediatric Drugs.2023; 25(5): 499. CrossRef
Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review
Phinga Do, John Andersen, Ashish Patel, Gaith Semrin, Luis Sifuentes-Dominguez, Phuong Luu, Bhaskar Gurram
F1000Research.2021; 9: 316. CrossRef
Ustekinumab Dose Intensification in Paediatric Crohn's Disease
Rosa Rodríguez‐Mauriz, Carlos Seguí Solanes, Isabel Masiques Mas, Nuria Rudi Sola
Journal of Paediatrics and Child Health.2021; 57(7): 1148. CrossRef

7,773 View
390 Download
9 Web of Science
10 Crossref

Inflammatory Bowel Diseases

Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan: Yosuke Shimodaira, Kengo Onochi, Kenta Watanabe, So Takahashi, Sho Fukuda, Noboru Watanabe, Shigeto Koizumi, Tamotsu Matsuhashi, Katsunori Iijima; Intest Res 2021;19(2):225-231. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00023

Abstract PDF PubReader ePub

Background/Aims
5-Aminosalicylic acid (5-ASA) is a basic drug for inducing and maintaining remission for ulcerative colitis. One of its formulations has a coating with a pH-dependent degradation that ensures the release 5-ASA at the terminal ileum. No evidence has been shown concerning the effects of proton pump inhibitors (PPIs) or H₂ receptor antagonists (H2RAs) on the clinical course of ulcerative colitis patients in remission. The present study assessed the effect of PPIs or H2RAs on the relapse of ulcerative colitis patients in clinical remission maintained by pH-dependent released 5-ASA.
Methods
Ulcerative colitis patients who had been prescribed time- or pH-dependent-released 5-ASA between January 2015 and December 2018 were enrolled in this multicenter retrospective study. The period of remission until relapse occurred was analyzed among the patients taking time-dependent-released 5-ASA or pH-dependent-released 5-ASA with/without PPIs or H2RAs.
Results
One hundred and nineteen patients were analyzed in this study. In the primary endpoint, the relapse rate was higher in patients taking pH-dependent-released 5-ASA and PPIs or H2RAs than in those taking the pH-dependent-released 5-ASA without PPIs or H2RAs, while the relapse rate was similar in patients taking the time-dependent-released 5-ASA with or without PPIs or H2RAs concomitantly. Patients with a short duration of disease and middle-aged patients more frequently showed relapse with PPIs or H2RAs than the other patients.
Conclusions
The coadministration of PPIs or H2RAs affects the clinical course of ulcerative colitis in remission maintained by pH-dependent-released 5-ASA.

Citations

Citations to this article as recorded by

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef
The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
Yuichiro Ohtaki, Kan Uchiyama, Hirotaka Kamiya, Eri Moriizumi, Moe Yamada, Yuma Aoki, Toshimune Watanabe, Sachie Kiryu, Shizuka Suzuki, Yoshihiro Matsumoto, Zensho Ito, Toshifumi Ohkusa, Shigeo Koido, Masayuki Saruta
BMC Gastroenterology.2022;[Epub] CrossRef

6,641 View
203 Download
3 Web of Science
2 Crossref

Inflammatory Bowel Diseases

Prospective validation of CD4⁺CD25⁺FOXP3⁺ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease: Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, Deepak Madhu, Amit Kumar Singh, Veena Tiwari, V. Pratap Mouli, Srikant Mohta, Govind Makharia, Vineet Ahuja; Intest Res 2021;19(2):232-238. Published online May 8, 2020; DOI: https://doi.org/10.5217/ir.2019.09181

Abstract PDF PubReader ePub

Background/Aims
Crohn’s disease (CD) and intestinal tuberculosis (ITB) remain “difficult-to-differentiate” diseases. We have previously documented peripheral blood frequency of CD4⁺CD25⁺FOXP3⁺ T-regulatory cells (Treg) as a biomarker to differentiate CD and ITB. We tried to validate these results in a larger cohort of CD and ITB patients.
Methods
Seventy treatment naïve patients of CD (n = 23) and ITB (n = 47) (diagnosed by standard criteria) were recruited prospectively from October 2016 to May 2017. Patients with history of antitubercular therapy in the past were excluded. The frequency of Treg cells in peripheral blood was determined by flow cytometry, and compared between CD and ITB patients.
Results
Similar to our previous study, frequency of Treg cells in peripheral blood was significantly increased in ITB as compared to CD patients (40.9 [interquartile range, 33–50] vs. 24.9 [interquartile range, 14.4–29.6], P< 0.001). Further, the receiver operating characteristics curve also showed good diagnostic accuracy with an area under the curve (AUC) of 0.77 (95% confidence interval, 0.65–0.89) and a FOXP3⁺ cutoff value of > 31.3% had a sensitivity and specificity of 83% and 82.6% respectively, to differentiate ITB from CD. Even for the indeterminate cases (n = 33), Treg cell frequency had similar diagnostic accuracy with an AUC of 0.85 (95% confidence interval, 0.68–0.95) and a cutoff of 32.37% had sensitivity and specificity of 87% and 95% respectively, to differentiate ITB from CD.
Conclusions
The current findings validate that the increased frequency of CD4⁺CD25⁺FOXP3⁺ Treg in the peripheral blood can be used as a biomarker with high diagnostic accuracy to differentiate ITB from CD.

Citations

Citations to this article as recorded by

New diagnostic strategies to distinguish Crohn's disease and gastrointestinal tuberculosis
Himanshu Narang, Saurabh Kedia, Vineet Ahuja
Current Opinion in Infectious Diseases.2024; 37(5): 392. CrossRef
Evidence-based approach to diagnosis and management of abdominal tuberculosis
Daya Krishna Jha, Mythili Menon Pathiyil, Vishal Sharma
Indian Journal of Gastroenterology.2023; 42(1): 17. CrossRef
Gut Microbiome in Probable Intestinal Tuberculosis and Changes following Anti-Tuberculosis Treatment
Hyuk Yoon, Young Soo Park, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
Yonsei Medical Journal.2022; 63(1): 34. CrossRef
Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
Tingming Cao, Guangming Dai, Hongqian Chu, Chengcheng Kong, Huijuan Duan, Na Tian, Zhaogang Sun
Hereditas.2022;[Epub] CrossRef
Recent advances in the diagnosis of intestinal tuberculosis
Hasan Maulahela, Marcellus Simadibrata, Erni Juwita Nelwan, Nur Rahadiani, Editha Renesteen, S. W. T. Suwarti, Yunita Windi Anggraini
BMC Gastroenterology.2022;[Epub] CrossRef
Addition of computed tomography chest increases the diagnosis rate in patients with suspected intestinal tuberculosis
Saurabh Kedia, Raju Sharma, Sudheer Kumar Vuyyuru, Deepak Madhu, Pabitra Sahu, Bhaskar Kante, Prasenjit Das, Ankur Goyal, Karan Madan, Govind Makharia, Vineet Ahuja
Intestinal Research.2022; 20(2): 184. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Intestinal tuberculosis or Crohn's disease: Illusion or delusion or allusion
Saurabh Kedia, Vineet Ahuja
JGH Open.2021; 5(2): 177. CrossRef
Deep‐learning system for real‐time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis
Jung Min Kim, Jun Gu Kang, Sungwon Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2021; 36(8): 2141. CrossRef
Mycobacterium tuberculosis (MTB) antigen-induced upregulation of interleukin-35 expression in patients with MTB infection: In vitro blockade of the effects of interleukin-35 on T lymphocyte subsets
Hongbin Jiang, Beinian Cui, Jun Zhang
Pathogens and Disease.2021;[Epub] CrossRef

6,537 View
136 Download
8 Web of Science
10 Crossref

Colorectal neoplasia

Postgastrectomy gastric cancer patients are at high risk for colorectal neoplasia: a case control study: Tae-Geun Gweon, Kyu-Tae Yoon, Chang Hyun Kim, Jin-Jo Kim; Intest Res 2021;19(2):239-246. Published online November 13, 2020; DOI: https://doi.org/10.5217/ir.2020.00009

Abstract PDF PubReader ePub

Background/Aims
Several studies have shown that colorectal neoplasms (CRN) including colorectal cancer (CRC) may be prevalent in patients with gastric cancer. However, in most of these studies, colonoscopy to investigate the prevalence of CRN was performed prior to surgery. We aimed to investigate whether CRN was more prevalent in postgastrectomy gastric cancer patients than in healthy individuals.
Methods
We reviewed the medical records of those patients within a cohort of gastric cancer patients with gastrectomy who underwent colonoscopy between 2016 and 2017. Controls age- and sex-matched with gastric cancer patients at a 2:1 ratio were identified among those who underwent colonoscopy at a health-promotion center. The frequencies of CRN, advanced CRN (ACRN), and CRC among patients with gastrectomy were compared with those in the control subjects. A total of 744 individuals (gastric cancer, 248; control, 496) were included.
Results
The rates of CRN and ACRN in the gastric cancer group were higher than those in the healthy individuals (CRN, 47.6% vs. 34.7%, P< 0.001; ACRN, 16.9% vs. 10.9%, P= 0.020). The rate of CRC was comparable between the 2 groups (2.0% vs. 0.6%, P= 0.125). Multivariate analysis identified previous gastrectomy for gastric cancer and male sex as significant risk factors for (A)CRN.
Conclusions
CRN and ACRN were more prevalent in patients who underwent surgery for gastric cancer than in the control group. Regular surveillance colonoscopy at appropriate intervals is indicated after gastrectomy.

Citations

Citations to this article as recorded by

Safety of cold snare resection techniques for removal of polyps in the small colon in patients taking clopidogrel and aspirin: a Korean Association for the Study of Intestinal Diseases prospective multicenter study
Tae-Geun Gweon, Hyun Gun Kim, Yunho Jung, Seong Ran Jeon, Soo-Young Na, Yoo Jin Lee, Tae Ho Kim
Gastrointestinal Endoscopy.2025; 101(4): 866. CrossRef
Effect of bowel preparation completion time on bowel cleansing efficacy: Prospective randomized controlled trial of different bowel preparation completion times precolonoscopy
Hye Min Kim, Hyo Suk Kim, Young Eun An, Jae Hyuck Chang, Tae Ho Kim, Chang Whan Kim, Tae‐Geun Gweon
Digestive Endoscopy.2024; 36(12): 1347. CrossRef
Calcium, Vitamin D, and Colorectal Cancer
Young-Jo Wi, Soo-Young Na
The Korean Journal of Gastroenterology.2023; 82(2): 47. CrossRef
Comparison of 2 L Polyethylene Glycol Plus Ascorbic Acid and 4 L Polyethylene Glycol in Elderly Patients Aged 60–79: A Prospective Randomized Study
Sung Hoon Jung, Chul-Hyun Lim, Tae-Geun Gweon, Jinsu Kim, Jung Hwan Oh, Kyu-Tae Yoon, Jee Young An, Jeong‑Seon Ji, Hwang Choi
Digestive Diseases and Sciences.2022; 67(10): 4841. CrossRef
Colonoscopy Insertion in Patients with Gastrectomy: Does Position Impact Cecal Intubation Time?
Jae Hyun Kim, Youn Jung Choi, Hye Jung Kwon, Gyu Man Oh, Kyoungwon Jung, Sung Eun Kim, Won Moon, Moo In Park, Seun Ja Park
Digestive Diseases and Sciences.2022; 67(9): 4533. CrossRef
Early gastric neoplasms are significant risk factor for colorectal adenoma: A prospective case-control study
Seong-Jung Kim, Jun Lee, Dae Youb Baek, Jun Hyung Lee, Ran Hong
Medicine.2022; 101(32): e29956. CrossRef
Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis
Peter P. Stanich, Dareen Elgindi, Elena Stoffel, Erika Koeppe, Ajay Bansal, Rachel Stetson, Debra L. Collins, Dana Farengo Clark, Eve Karloski, Beth Dudley, Randall E. Brand, Michael J. Hall, Yana Chertock, Brian A. Sullivan, Charles Muller, Alice Hinton,
American Journal of Gastroenterology.2022; 117(11): 1877. CrossRef

5,285 View
115 Download
8 Web of Science
7 Crossref

Case Report

IBD

Non-cirrhotic portal hypertension related to azathioprine therapy in a patient with Crohn’s disease: Jong Won Seo, Eun Soo Kim, Man-Hoon Han, Young Oh Kweon; Intest Res 2021;19(2):247-251. Published online July 2, 2020; DOI: https://doi.org/10.5217/ir.2020.00016

Abstract PDF PubReader ePub

Azathioprine is widely used for the treatment of Crohn’s disease (CD). Few cases from Western countries have reported idiopathic non-cirrhotic portal hypertension (NCPH) related to thiopurine therapy in patients with inflammatory bowel disease. Idiopathic NCPH is a rare hepatic condition with intrahepatic portal hypertension but no evidence of cirrhosis or chronic liver disease. Patients with idiopathic NCPH present with symptoms of portal hypertension such as thrombocytopenia, splenomegaly and esophageal varices. We report a case of idiopathic NCPH in a 51-year-old male patient with CD who had been taking azathioprine for 5 years. He was admitted due to esophageal variceal bleeding along with splenomegaly and thrombocytopenia. Evaluation of cirrhosis or chronic liver disease showed normal-range results as estimated by FibroScan evaluation, laboratory examination for autoimmune hepatitis or viral hepatitis, and liver biopsy. This case may suggest the need for careful monitoring for manifestations of portal hypertension in Asian patients with inflammatory bowel disease receiving thiopurine treatment.

Citations

Citations to this article as recorded by

Non-cirrhotic Idiopathic portal hypertension in systemic sclerosis patients: report of one case and a systematic review of previous case reports
Felipe Souza da Silva, João Victor de Pinho Costa, Carlos Alberto dos Santos Júnior, Érika Emmylaine dos Santos, Ailton José de Castro Júnior, Ana Cecília de Sena Oliveira, Flávia Patrícia Sena Teixeira Santos, Adriana Maria Kakehasi, Débora Cerqueira Cal
Advances in Rheumatology.2025;[Epub] CrossRef
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease – A comprehensive narrative review
Nicola Pugliese, Lucia Giuli, Elisabetta Mastrorocco, Francesco Santopaolo, Giacomo Marcozzi, Cristina Bezzio, Arianna Dal Buono, Roberto Gabbiadini, Antonio Gasbarrini, Francesca Romana Ponziani, Alessandro Armuzzi, Alessio Aghemo
Digestive and Liver Disease.2024; 56(6): 964. CrossRef
Non-Cirrhotic Portal Hypertension: an Overview
Sajid Jalil, Ashwani K. Singal
Current Hepatology Reports.2024; 23(1): 153. CrossRef
Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
Gut and Liver.2024; 18(2): 294. CrossRef
A Narrative Review on Non-Cirrohotic Portal Hypertension: Not All Portal Hypertensions Mean Cirrhosis
Michele Fiordaliso, Giuseppe Marincola, Barbara Pala, Raffaella Muraro, Mariangela Mazzone, Maria Carmela Di Marcantonio, Gabriella Mincione
Diagnostics.2023; 13(20): 3263. CrossRef
Nichtzirrhotische portale Hypertension – Ursachen und praktisches Management
A. Queck, J. Trebicka
Der Gastroenterologe.2021; 16(2): 90. CrossRef

6,284 View
143 Download
5 Web of Science
6 Crossref

Images of the Issue

Miscellaneous

Bloating in a supine position: Akira Hokama, Yasuka Nakada, Aki Yanagida, Erika Koga, Kunikazu Hoshino, Jiro Fujita; Intest Res 2021;19(2):252-253. Published online June 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00019

PDF PubReader ePub

10,763 View
1,520 Download

First
Prev
Page of 1
Next
Last

Previous issues